Human embryonic stem cells (hESC) are pluripotent stem cells. A major challenge in the field of hESC is the establishment of specific differentiation protocols that drives hESC down a particular lineage fate. So far, attempts to generate T cells from hESC in vitro were unsuccessful. In this study, we show that T cells can be generated in vitro from hESC-derived hematopoietic precursor cells present in hematopoietic zones (HZs). These zones are morphologically similar to blood islands during embryonic development, and are formed when hESC are cultured on OP9 stromal cells. 
H uman embryonic stem cells (hESC) 3 are derived from early stage blastocysts and are characterized by the ability to both self-renew and to generate differentiated functional cell types (1) . hESC provide a unique and unlimited starting population of cells for studying human hematopoiesis, and hESC-derived blood products could therefore be created in virtually unlimited amounts. In the past years, several culture systems have been developed that allow hESC to differentiate into hematopoietic precursor cells (HPC) in vitro. The three-dimensional embryoid body system and coculture systems on stromal cell lines such as murine OP9 cells or aorta-gonad-mesonephros-derived stromal cells are often used (2, 3) . In both systems, multipotent HPC with self-renewing activity were demonstrated (4, 5) . Vodyanik et al. (6) performed an extensive analysis of precursors generated from hESC in OP9 coculture and described a CD34 ϩ
CD43
ϩ population, with precursor activity for B, NK, and myeloid cells. Although T precursor activity was not addressed, these data suggest that the CD34 ϩ CD43 ϩ population may contain multipotent HPC. However, a recent report from Martin et al. (7) indicated that such hESC-derived HPC lack T lineage potential. hESC-derived CD34 ϩ cells, introduced in fetal thymic organ cultures or in cocultures with Delta-like 1 expressing OP9 stromal cells (OP9-DL1), did not generate T cells, in contrast to cord blood-derived CD34 ϩ cells. In two reports from Galic et al. (8, 9) , an in vivo model was used to demonstrate T cell potential of HPC, which were generated in vitro from hESC. hESC-derived HPC were injected into human thymus/fetal liver grafts in SCID-hu mice. This study showed that CD3 ϩ cells and CD4 CD8 double positive T cell precursors were generated 3 to 5 wk after injection. However T cell lymphopoiesis was much less efficient than what has been observed with HPC from bone marrow (BM) or umbilical cord blood (10) .
In this study, we readdress the issue whether T cells can be generated in vitro from hESC. We used the protocol as described by Vodyanik (6) to generate HPC from hESC on OP9 stromal cells. During the course of these experiments we noted the formation of endothelium-lined cell clumps, reminiscent of blood islands during embryonic development, which we termed hematopoietic zones (HZs). These structures have since been described by two other groups and were shown to contain HPC with self renewing capacity and HPC capable of generating massive amounts of megakaryocytes (5, 11) . In this study, we report that these HZs generate large numbers of T cells when transferred on OP9-DL1 cells in the presence of growth factors.
Furthermore, we show that the T cells are generated from CD34 high CD43 low cells present in these HZs, suggesting that these cells contain multipotent HPC.
Using the approach described in this study, T cell differentiation from hESC is now easily amenable to manipulation and the principles governing differentiation can be studied. In addition, generation of T cells from hESC may be clinically relevant, especially when autologous cells with similar characteristics, such as induced pluripotent stem cells (iPS cells) (12) , can be used.
Materials and Methods

Cell line cultures
All experiments were performed in accordance with the guidelines of the Medical Ethical Commission of Ghent University Hospital (Belgium). For this study, the hESC line H1 (National Institutes of Health code: WA01) was used (Passage 30 -60). The hESC line was kept in an undifferentiated state on MEFs as previously described (1) . The H1 cell line displayed stable growth, colony morphology, karyotype, and expression of surface markers such as SSEA-3 and SSEA-4 (data not shown). OP9 cells and OP9-DL1 cells (a gift from Juan Carlos Zúñ igaPflü cker, University of Toronto, Canada) were cultured as previously described in MEM-␣ with 20% FCS and supplemented with L-glutamine and the antibiotics streptomycin and penicillin (all from Invitrogen) (13) .
Generation of HZs from hESC and transfer onto OP9-DL1
To differentiate hESC into CD34 ϩ cells, the protocol from Vodyanik et al. (3) was adapted. In brief, subconfluent hESC cultures were mechanically fragmented into small clumps using glass beads (SigmaAldrich) and incubated on overgrown OP9 cells in six-well plates precoated with 0.1% gelatin (Sigma-Aldrich). To estimate the number of hESC incubated on OP9 cells, hESC cultures grown from the same split/passage were used to obtain single cell suspension for counting. An average of 2 ϫ 10 5 hESC were incubated per well of a six-well plate. After 10 -12 days of culture on OP9 cells, HZs were picked up under microscopic inspection using a small scalpel and pipette. The pooled HZs (average of 5,000 CD34 ϩ CD43 ϩ cells) were transferred onto subconfluent OP9-DL1 cultures in 12-well plates with MEM-␣, 20% FCS, and supplemented with fms-like tyrosine kinase 3 receptor ligand (FLT3-L: 5 ng/ml; PeproTech), rhIL-7 (5 ng/ml; R&D Systems), and 10 ng/ml stem cell factor (SCF) (Amgen). After 5-7 days of culture, the HPC within the HZs were released by gently pipetting and incubated on a fresh OP9-DL1 monolayer for up to 6 wk. Every 3 days, half of the medium was changed, and every 5-7 days, cells were transferred on a fresh OP9-DL1 monolayer.
For the kinetic studies in Figs. 3K and 4B, a large number of HZs from OP9 cultures were pooled together. To estimate the number of CD34 ϩ
CD43
ϩ within this HZs pool, half of the collected HZs were dissociated and counted with a flow cytometer. An average of 5000 CD34 ϩ CD43 ϩ cells were incubated in each quantitative experiment. Microscopic images were recorded with a CCD camera (Moticam 480, Motic) using phasecontrast microscopy (Leica Microsystems).
Flow cytometry and cell sorting
For cell analysis, the cells were mechanically dissociated without use of enzymes. Before adding Ab, FcR blocking was performed using human IgG (Miltenyi Biotec sorted using stringent gates as shown in Fig. 5 . The results were analyzed using CellQuest Software or FACSDiva version 6.1.1 (BD Biosciences). The following (conjugated) anti-human mAbs were used: CD1a-allophycocyanin; CD3-allophycocyanin,-PE,-FITC,-allophycocyanin-Cy7; CD4-allophycocyanin,-PE,-FITC,-PE-Cy7; CD7-allophycocyanin,-PE,-FITC,-biotinylated; CD8␣-allophycocyanin; CD8␣-PE; CD8␤-PE,-allophycocyanin; CD10-PE; CD10-PECy7, CD11b-PE; CD11c-PE; CD14-PE; CD15-PE; CD16-PE; CD19-PE; CD26-PE; CD27-PE,-biotynilated; CD31 (PECAM-1)-PE,-FITC; CD33-PE; CD34-allophycocyanin, -PE, -FITC; CD36-PE; CD38-PE; CD41a-PE; CD43-FITC; CD45RA-allophycocyanin,-PE; CD45-allophycocyanin,-PE,-FITC; CD54 (ICAM-1)-PE; CD56-allophycocyanin,-PE, FITC,-PE-Cy7; CD66-PE, CD80-PE; CD90-PE; CD106 (VCAM-1)-PE, CD117-PE (c-kit),-biotinylated; CD122 (IL-2R␤)-PE; CD123 (IL-3R)-PE; CD127 (IL-7R)-PE; CD132-PE; CD133-PE; CD135-PE; CD144 (VE-Cadherin)-PE; CD146 (MUC-18)-PE CD161-PE; CD184 (CXCR-4)-PE; CD235A (GlycophorinA)-PE; CD309 (KDR/vascular endothelial growth factor receptor (VEGFR)-2)-PE; SSEA1-PE, SSEA3-PE, SSEA4-PE, and TCR␤-PE. The mAbs were purchased from BD Pharmingen, Beckman Coulter, eBioscience, Miltenyi Biotec, and R&D Systems. The streptavidine labels (SA-PE-Cy5.5, SA-allophycocyaninCy7) were purchased from eBioscience. The mAbs V␤-2,-5,-7,-12,-13,-17,-22 were purchased from Beckman Coulter.
Real time RT-PCR
Real-time RT-PCR analysis was performed on bulk cultures in the CD4 ϩ CD8␤ ϩ double positive (DP) stage (day 30 on OP9-DL1). RNA was extracted using the RNease Mini Kit (Qiagen). cDNA was synthesized using Superscript First Strand synthesis system (Invitrogen). Primers were designed using Primer Express 3.0 software (Applied Biosystems) and manufactured by Operon. Gene and cDNA specificity of the primers was checked using NCBI-BLAST and GENATLAS, available on the internet.
The following primer pairs were used: GAPDH sense: TCCTCTGACT TCAACAGCGACA; GAPDH antisense: GTGGTCGTTGAGGGCAATG; RAG-1 sense: CCTGCTGAGCAAGGTACCTCA; RAG-1 antisense: ATCTGGGGCAGAACTGAGTCC; RAG-2 sense: TGGTTTAGCGG CAAAGATTCA; RAG-2 antisense: AGTTTCTGATGGTACGTAGA FIGURE 2. FACS analysis of differentiating hESC on OP9 and OP9-DL1 cells. A representative FACS analysis of HZs generated after 12 days on OP9 cells is shown in A (n ϭ 4). Four cell populations are gated: R1 (13% of the cells), R2 (2%), R3 (3%), and R4 (3%). An extensive analysis of the R2 and R3 gated CD34 ϩ CD43 ϩ fractions is shown for the indicated cell markers. A more detailed analysis of all populations gated in A is available in supplemental Table S1 . The fraction of CD34 high CD43 low and CD34 low CD43 high cells within the total CD34 ϩ CD43 ϩ cells after 10 -12 days on OP9 cells was very constant: 30 to 40% for CD34 high CD43 low cells and 60 to 70% for the CD34 low CD43 high cell fraction. B, Representative FACS analysis of non-hematopoietic zones (Non-HZs) generated from hESC after 12 days on OP9 cells (n ϭ 6). In C, a representative FACS analysis on transferred HZs at day 6 of culture on OP9-DL1 cells is shown (n ϭ 3). TTTTTGTC; pT␣ sense: GCCCATGCATCTGTCAGGAG; pT␣ antisense: ATCCACCAGCAGCATGATTG.
PCR reagents and SYBR Green I mastermixes were obtained from Eurogentec and used according to the manufacturer's instructions. The reactions were run on an ABI Prism 7300 Sequence Detection System (Applied Biosystems). The following cycling conditions were used: 10 min at 95°C, 40 cycles at 95°C for 15 s, and 60°C for 60 s. After amplification, a melting curve was generated for every PCR product and compared with melting curve of positive control cells (human thymus). Negative control cells included undifferentiated hESC, the murine OP9-DL1 cells, and CD31 ϩ
CD146
ϩ CD45 Ϫ EC generated in vitro from hESC. The relative expression was calculated for each gene by the ⌬Ct method.
GeneScan analysis
DNA was purified according to the manufacturer's instructions (GenElute Mammalian Genomic DNA Miniprep Kit, Sigma-Aldrich) from bulk cultures at day 30 of coculture on OP9-DL1 (n ϭ 3). The GeneScan was performed by two multiplex PCR as previously described by the BIOMED-2 Concerted Action (14) . Each analysis was performed in duplo, including hESC and adult PBMC as negative and positive control, respectively.
Functional testing of T cells
hESC-derived T cells were expanded on a feeder mixture consisting of irradiated JY cells and adult HLA-A2 negative PBMC cells (40 and 50 Gy, respectively) and stimulated with PHA (1 g/ml; Sigma-Aldrich) in IMDM (Invitrogen), supplemented with 10% FCS. After 4 days, IL-2 (40 U/ml) (BD Pharmingen) was added and refreshed every 4 days. The cells were restimulated every 12 days using the same protocol. To test for cytoplasmatic IFN-␥ production, hESC-derived T cells were subsequently incubated on anti-CD3 coated 96-wells, and soluble anti-human CD28 and anti-human CD49d mAbs, according to the protocol of the supplier (BD Pharmingen). After 1 h, GolgiPlug (BD Pharmingen) was added and after an additional 5 h, cells were analyzed with FACS LSR II (BD Pharmingen). Because the H1 cell line expresses HLA-A2, a gate was set on the HLA-A2 ϩ cells for analysis. Staining for cytoplasmatic IFN-␥ was performed according to the manufacturer's instructions (Cytofix/Cytoperm kit; BD Pharmingen) with anti-human IFN-␥-FITC or FITC Mouse IgG1, Isotype Control (BD Pharmingen) and anti-human CD3-PE (BD Pharmingen).
Statistical analysis
A Mann-Whitney U test was performed with SPSS 15.0 software, and a p-value Ͻ0.05 was considered as statistical significant. hematopoietic cells. hESC colonies (Fig. 1, Step 1) were fragmented into small clumps and incubated on OP9 monolayers to allow hematopoietic development (Fig. 1, Step 2) . During the hESC/OP9 coculture period, well-organized two-dimensional structures were formed that strongly mimicked blood islands, which arise during normal embryonic development (15) (Fig. 1B) . These blood island-like structures consisted of a central core of mostly CD34 ϩ round cells surrounded by a rim of CD34 ϩ flat endothelial-like cells (Fig. 1C) . Similar structures were recently described as ES-sacs and were shown to contain precursors for megakaryocytes (11) . We could demonstrate by flow cytometric analysis the presence of CD34 ϩ CD43 ϩ HPC cells within the blood island-like structures that were mechanically picked up from the hESC/OP9 cultures ( Fig. 2A) , but not within areas that did not display such structures (Fig. 2B) . This indicates that all CD34 ϩ
Results
CD43
ϩ HPC cells generated on the OP9 cells were confined to these structures. Therefore, we referred to these structures as HZs (Fig. 1, B and C) .
Based on the expression of CD43 and CD34, distinct cell populations can be identified within the HZs at day 10 -12 on OP9 cells (Fig. 2A, gate R1-R4 ). An extensive flow cytometric analysis of the gated populations is shown in supplemental Table S1. 4 We could confirm, as was previously described (6) , that the R1 CD34
high CD43 Ϫ population depicted in Fig. 2A comprises CD31 ϩ CD146 ϩ CD45 Ϫ endothelial cells, whereas the CD34 Ϫ CD43 ϩ cells (R4 in Fig. 2A ) represents CD41 ϩ GlycA(CD235A) ϩ erythro-megakaryocytic lineage cells (supplemental Table S1 and data not shown). We consistently detected two major CD34 ϩ CD43 ϩ cell populations: a CD34 high CD43 low cell population (R2 in Fig. 2A ) that expressed variable levels of CD45 and c-kit (CD117), and a CD34 low CD43 high cell subset (R3 in Fig. 2A ) which was mostly devoid from CD45 and c-kit expression. The kinetics of appearance of the R2 population in the hESC OP9 coculture system is shown in supplemental Fig. 1A . B cell and myeloid lineage markers were absent (supplemental Table S1 ). Although CD56 was expressed on the majority of CD34 high CD43 low cells, we do not consider this evidence for NK commitment but rather as a remnant of CD56 expression by undifferentiated hESC. The fact that CD34
ϩ CD43 ϩ cells were negative for the early NK lineage marker CD161 supports this interpretation (supplemental Table  S1 ). Both CD34 ϩ CD43 ϩ cell subsets expressed the lymphoid lineage marker CD7, albeit at a different frequency and intensity, but expression of cytoplasmic CD3 (cyCD3) within these cell populations was never detected (Fig. 2A) . These phenotypical data are compatible with the CD34 high CD43 low population being an uncommitted HPC population.
Transfer of HZs on OP9-DL1 cells generates early T lineage precursors
The crucial role of Notch signaling in hematopoietic cell fate decisions and T lymphocyte development in particular has been well established (13, 16, 17) . Therefore, we picked up the HZs that contain CD34 high CD43 low HPC and transferred them in toto onto OP9-DL1 monolayers to allow further HPC development and T lineage commitment (Fig. 1, Step 3) (n ϭ 9) . Approximately 5-7 days following transfer onto the OP9-DL1 cells, the HZs/OP9-DL1 cocultures (Fig. 1, D and E) were disrupted mechanically to release the hESC-derived cells. Flow cytometric analysis at that stage showed the typical CD34 high CD45 ϩ HPC phenotype. The cells no longer expressed CD43, but coexpressed c-kit, a marker known to be present on HPC and early T cell precursors (Fig. 2C) . Expression of cyCD3 was detected within CD34 high CD45 ϩ c-kit ϩ CD7 ϩ cells (R2 in Fig. 2C ), but not in Fig. 2C ), suggesting T/NK lineage commitment of these CD34
ϩ cells on OP9-DL1 monolayers (18) . Importantly, prolonged culture of the HZs on the initial OP9 cells 4 The online version of this article contains supplementary material. or following their transfer onto fresh OP9 monolayers did not sustain (or generate) CD34 high CD45 ϩ CD7 ϩ cells, and CD45 ϩ CD15 ϩ myelo-monocytic cells developed instead (supplemental Fig. S1 , B and C). These findings indicate that DL1 triggers HPC within the HZs and specifically promotes the generation of early CD34 high CD45 ϩ CD7 ϩ c-kit ϩ cyCD3 ϩ T/NK progenitors. Furthermore, incubation of "Non-HZs" on OP9-DL1 did not yield CD45 ϩ cells, again confirming that HPC were confined to the HZs (supplemental Fig. S1D ).
hESC-derived HZs give rise to CD4
ϩ CD8␤ ϩ DP and TCR␣␤ S1E ) and a significant cyCD3 ϩ CD5 ϩ subpopulation (Fig. 3, A-D) . The first CD4 single positive cells and CD4 ϩ CD8␣␣ ϩ DP T lineage cells were detected within the cyCD3 ϩ CD5 ϩ cell population after 14 days, suggesting that this CD5 ϩ population contains T-committed precursors (Fig. 3E) . After 21 days, CD4
ϩ CD8␣␤ ϩ DP cells emerged in the cultures and on day 28, DP cells were prominent (Fig. 3, F and G) .
Past day 30, the proportion of CD3
ϩ TCR␣␤ ϩ cells in these cultures ranged between 15 and 50% of all human cells (Fig. 3, H and  K) . In addition to CD3 ϩ TCR␣␤ ϩ cells, CD3 ϩ TCR␥␦ ϩ appeared in all experiments (Fig. 3, I and K) (n ϭ 9). In Fig. 3K , it is shown that 5000 HPC expand to about one hundred times that number of DP cells. At the mRNA level, pT␣, RAG-1, and RAG-2 became detectable with the appearance of DP cells (Fig.  3J) , supporting the notion that T cells were generated de novo in these cultures. These data clearly show that hESC can differentiate to T lineage cells in vitro. Furthermore, the developmental pathway of these cells appears to be similar to thymic development (19) .
A hESC-derived CD34 high CD43 low cell population generates T lineage cells
Next, we investigated which CD34
ϩ subset in the HZs contains the T lineage precursors. Because the CD34 high CD43 low cell population described above has a phenotype reminiscent of adult HPC, we hypothesized that the T lineage cells generated in our system may develop from this population. Indeed, cell sorting experiments clearly demonstrated that the CD34 high CD43 low cells differentiated into T lineage cells when transferred on OP9-DL1 monolayers, Because the CD34 high CD43 low cell population is endowed with T cell potential and coexpresses the receptor c-kit, we reasoned that adding the c-kit ligand SCF might improve the generation of T lineage cells from hESC in our system. When adding SCF (10 ng/ml) to the OP9-DL1 cocultures, a dramatic increase in the absolute (Ͼ80-fold) and relative number (Ͼ14-fold) of CD4 ϩ
CD8␤
ϩ DP cells was observed compared with cultures without SCF ( Fig. 4B ; p Ͻ 0.05). Moreover, a Ͼ180-fold and 15-fold absolute increase of hESC-derived CD3 ϩ TCR␣␤ ϩ and CD3 ϩ TCR␥␦ ϩ cells, respectively, was observed in the SCF-supplemented cultures ( Fig. 4B ; p Ͻ 0.05) (n ϭ 3).
CD10 was reported to mark early lymphoid committed cells present in bone marrow, blood, and thymus (20, 21) . We therefore analyzed whether CD10 ϩ cells could be detected in HZ. However, no CD10 expression could be observed on CD34
high CD43 low precursor in days 10 -12 HZ (supplemental Table S1 , supplemental Fig. S2A ). We subsequently analyzed whether such CD10 ϩ cells were generated from CD34 high CD43 low cells on OP9-DL1. Transferred cells remained consistently negative for CD10 expression (supplemental Fig. S2A ), suggesting that the induction of CD10 on CD34
ϩ cells requires signals that are not present in OP9-DL1 cultures.
Acquisition of the surface marker CD7 on CD34 ϩ HPC has been shown to be one of the earliest steps in T cell ontogeny (19, 21 (Fig. 5A) . However, as shown in Fig. 3 , A-D, after transfer of CD34 high CD43 low cells on OP9-DL1 feeders, cells rapidly acquire CD7 and become CD7 high cyCD3 ϩ cells, which give rise to the later stages of T cell development (Figs. 2C and 3 ). This suggests that expression of a marker by itself does not signify lymphoid commitment.
In the hESC/OP9 system, it was shown that CD34 ϩ CD43 ϩ CD45 Ϫ precursors represent early HPC with lympho-myeloid potential (6) . Acquisition of the surface marker CD45 on these cells (yielding CD34 ϩ
CD43
ϩ CD45 ϩ cells) was accompanied by loss of B-lymphoid potential and progressive myeloid commitment. We therefore assessed whether acquisition of CD45 was accompanied with loss of T cell lineage potential. Both CD34 high CD43 low CD45 Ϫ and CD34 high CD43 low CD45 ϩ subsets were sorted (n ϭ 3) and cultured on OP9-DL1 to generate T lineage cells. Both cell populations generated DP cells and CD3 ϩ T cells (Fig. 5B) . The absolute cell number of CD4 ϩ CD8␣␤ ϩ DP, CD3 ϩ TCR␣␤ ϩ , and CD3
ϩ TCR␥␦ ϩ cells generated from CD34 high CD43 low CD45 ϩ cells was 4-, 3-, and 2-fold higher compared with the respective populations generated from CD34 high CD43 low CD45 Ϫ cells ( p Ͻ 0.05).
hESC-derived T lineage cells are polyclonal and functionally mature
In the thymus, T cells are generated in a polyclonal fashion to allow the recognition of a broad range of Ags via the TCR. The genetic loci encoding the TCR undergo sequential genomic rearrangements, with randomly chosen variable (V), diversity (D), and joining (J) segments being assembled to form a variable TCR repertoire (14) . To test whether the hESC-derived T lineage cells display a polyclonal repertoire, we performed a GeneScan analysis. The data in Fig. 6A show diverse and random D-J and V-DJ rearrangements at the ␤ locus, indicating a polyclonal T lineage repertoire at the DNA level. Furthermore, flow cytometry confirmed a diverse and random V␤ family usage at the protein level (Fig.  6B) . Therefore, these data provide strong evidence that the hESCderived T lineage cells follow a stochastic pattern of gene rearrangement and do not result from the outgrowth of a single or a few T cells. Maturation status of the CD3 ϩ T cells was assessed both phenotypically and functionally. T cells develop into phenotypically mature cells as defined by the up-regulation of CD27 and downregulation of CD1a (22, 23) . Similar to thymic differentiation, hESC-derived T cells developed into a mature CD27 ϩ CD1a Ϫ phenotype (Fig. 6C) (n ϭ 9) , suggesting that functionally mature cells are present. After stimulation with PHA, hESC-derived T cells proliferated and increased a 2500-fold (supplemental Fig. S2B ). All CD3 ϩ cells had the mature CD27 ϩ CD1a Ϫ phenotype and both TCR␣␤ and TCR␥␦ positive cells were expanded (data not shown). Moreover, when these expanded cells were restimulated, IFN-␥ production could be demonstrated by flow cytometry (Fig.  6, D and E) , demonstrating that these cells have acquired functional characteristics of mature T cells.
Discussion
We report in this study that hESC have the potential to differentiate in vitro into T cells. To achieve this, hESC were first differentiated on OP9 cells to CD34 high CD43 low HPC cells in HZs. Before these cells had lost multipotency and had "spontaneously" differentiated to myeloid cells, days 10 -12 HPC cells were transferred to a DL1 environment in the presence of SCF, fms-like tyrosine kinase 3 receptor ligand, and IL-7. Under these conditions, cells became gradually committed to the T/NK lineage and generated large numbers of T cells. T cells displayed both the TCR␣␤ and TCR␥␦ phenotype, and were functional and polyclonal.
HPC were generated on OP9 cells exclusively in hematopoietic sites, which we referred to as HZs. For these HZs to form, it is essential that the hESC/OP9 cell cultures are, apart from medium changes, not manipulated until these HZs are fully established. Similar structures were recently described by two other groups. Ledran et al. (5) described "endothelial vessel structures" that emerged on mitotically inactivated primary or established stromal cell lines from murine aorta-gonad-mesonephros and fetal liver. The developmental kinetics of these structures were slower than reported in this study, as they were first visible on day 18. However, this coincided with the peak of CD34 ϩ cell numbers and hematopoietic precursor activity.
Takayama et al. (11) designated similar hematopoietic sites as ES-sacs. The ES-sacs were obtained after coincubation of hESC with OP9 or C3H101/2 stromal cells and appeared around day 15 of culture. The ES-sacs were reported to be lined by endothelial cells as suggested by their morphology and CD31 ϩ VEGFR-2 (CD309) ϩ UEA-1 ϩ phenotype and to contain round CD31 ϩ cells with some expression of CD34, VEGFR-2 (CD309), CD41a, and CD45. Both these papers report either a much higher yield in NOD/SCID repopulating activity (5) or in platelet production (11) compared with hESC differentiation protocols that do not allow the generation of these structures, suggesting that these structures are very efficient in the differentiation of ESC to HPC and/or proliferation of HPC. Recently, Galic et al. (8, 9) reported on the generation of T cells from hESC. hESC were predifferentiated to CD34 ϩ cells on OP9 cells or using a serum-free embryoid system, and it was demonstrated that after in vivo injection of CD34 ϩ cells in SCID-hu thymus, CD3
ϩ and CD4 ϩ CD8 ϩ DP cells were generated. In this study, we confirm and extend this observation by showing that these HZs also efficiently generate precursors for T cells.
It is unclear whether at any given time hematopoietic stem cells (HSC), defined as multipotent, self renewing cells that express certain membrane markers such as CD34, CD45, and CD133, are present in the HZs generated on OP9 cells. Cells having identical membrane markers as BM stem cells are not stably present in OP9 cultures. On the one hand, cells with hematopoietic precursor activity seem to partially retain membrane molecules of their hemogenic or hemangioblastic precursors, such as VE-cadherin and VEGFR-2 (supplemental Table S1 ) (15) . This is different from the BM stem cell compartment, where hematopoietic stem cells are believed to be no longer continuously generated from precursors and are devoid of these markers (24, 25) . In contrast, they acquire membrane markers such as CD45, which are expressed on all postnatal HSC/HPC. However, acquisition of CD45 in hESC/OP9 cultures was reported to be associated with loss of lymphoid precursor capacity, suggesting that differentiation to CD34 high CD45 ϩ cells may be preceded by loss of multipotency in the OP9 culture system (6). In our hands, however, cell sorting experiments showed that both CD45 ϩ and CD45 Ϫ fractions of the CD34 high CD43 low population have T cell potential. Furthermore, when CD34 high CD43 low cells were transferred to OP9-DL1 cultures, CD34 high CD45 ϩ cells were generated, which seem to have retained lymphoid differentiation potential.
Vodyanik et al. (6) performed an extensive functional analysis of the CD34 high CD43 low cell population. They showed that these cells had CFU-GEMM, CFU-M, CFU-GM and some CFU-E activity. In addition, after MS5 differentiation cocultures they could show NK generation and expression of early B lineage specific markers, suggesting that these cells also contain NK and B cell precursor activity. In this study, we show that this same population can generate functionally mature TCR␥␦ and TCR␣␤ cells. Therefore, it seems that precursor activity for all hematopoietic lineages is present within this CD34 high CD43 low population. Because to our knowledge, clonal analysis was never performed, it is not known whether a single multipotent HSC or rather a mixture of committed cells is responsible for the observed phenomena. Self renewal of human HSC, a characteristic feature of stem cells, is usually addressed by injecting these cells in NOD/SCID mice. Several reports have shown that hESC-derived HPC can repopulate NOD/ SCID mice and that cells from the BM of these reconstituted mice can be used successfully for secondary transfer, suggesting that self renewing cells are present in the hESC-derived HPC (5, 26).
However, as discussed by the authors, expression of adult globin in red lineage cells was absent, and definitive proof of lymphoid engraftment was lacking (5) . Therefore, to the best of our knowledge, formal proof of the existence of hESC-derived HSC is still lacking.
Based on the above discussion, we hypothesize that multipotent hematopoietic stem cells with self renewing capacity are transiently present in the HZs or ES-sacs and that the exact phenotype of these CD34 high CD43 low cells may vary and/or depend on the duration of culture. We have shown in this study that ESC-derived HPC can generate T cells when transferred at the right time to an environment that expresses DL1.
However, in a report of Martin et al. (7), predifferentiated hESC cells on the S17 stromal lines were devoid of T cell precursor activity tested in coculture with OP9-DL1 and in fetal thymic organ culture in vitro. Whether this relates to the specific characteristics of the hESC line used, or the developmental time window by which CD34 are harvested from the stromal cell line is unclear. Nevertheless, in our hands, hESC-derived CD34 ϩ cells generated on the S17 cell line after 10 -12 days, displayed similar T cell differentiation capacity compared with hESC-derived CD34 ϩ cells generated on OP9 (supplemental Fig. S3 ).
CD7 has been used extensively for the identification of lymphoid precursors within CD34 ϩ HPC. Such cells were found in fetal BM and in cord blood (27) . More recently, these populations were studied in the thymus: it was found that CD34 ϩ CD7 Ϫ cells are multipotent, CD34
ϩ CD7 int cells are lymphoid precursors including B cell precursor activity and the CD34 ϩ CD7 high population consists of T/NK precursors (21) . In contrast with these findings, we found CD7 in the HZs (step 2 cultures) not to be a good marker of lymphoid commitment: CD7 was preferentially expressed on R3 cells ( Fig. 2A) , which do not generate T or NK cells. In addition, sorted CD34 ϩ CD43 ϩ CD7 ϩ R2 cells were unable to generate T cells. We therefore believe that CD7 expression in the HZs is "aberrant", similar to CD56 expression. However, after transfer of CD34 ϩ CD43 ϩ cells on OP9-DL1 stromal cells, cells rapidly acquire CD7 and become CD7 high . CD7 expression is then accompanied with another T/NK lymphoid marker, i.e., cyCD3. Although unproven, it is likely that these cells are the first cells which are lymphoid lineage committed and therefore in these cultures, cyCD3 appears to be a better marker.
Once the cells are T/NK committed, differentiation follows the phenotypes as described in postnatal thymus. In contrast to postnatal thymopoiesis, CD1a expression is somewhat delayed as it first appears after, rather than before, CD4 expression and is therefore not the first marker for T commitment (data not shown). Similarly, CD1a disappears before the mature cells express CD27, rather than, as is observed in postnatal thymus, after CD27 expression. Interestingly, a similar expression pattern of CD1a is seen when fetal liver cells are differentiated to T cells on OP9-DL1 (data not shown).
We believe the protocol as described in this study is an important new tool for future research and for the design of immunotherapy. The hESC/OP9 system allows the direct visualization of HZs and the generation of T cells from these structures. These in vitro observations may significantly improve our insights on the early steps in human developmental hematopoiesis. Indeed, in combination with genetic cell tracing strategies, the direct visualization of the HZs may allow the identification of the cellular participants and/or crucial gene expression at these hematopoietic sites (28) . This system may also provide an opportunity in the field of immunotherapy where hESC-derived T cells could be engineered to express a TCR that recognizes a specific epitope expressed by malignant tumor cells (29) . These engineered hESCderived T cells could then be used to target cancer. Although it is currently possible to generate such T cells from cord blood or BM from children, BM from older adults is less efficient in generating T cells (30) . If the protocol described in this study could be applied to the differentiation of iPS cells, then these iPS cells would be the best source for the generation of tumor-specific T cells in older adults.
